Figure legends:
Figure 1. CD15+LOX-1+ PMN-MDSC
frequency in the circulation of healthy donors and NSCLC patients.
The frequency of circulating
CD15+LOX-1+ PMN-MDSCs in healthy
donors (n=50) and NSCLC patients (n=50) were measured by FCM. (B)ARG1 expression was detected in PB of healthy donors (n=50) and
NSCLC patients (n=50). (C) The correlation analysis between
CD15+LOX-1+ PMN-MDSC frequency andARG1 expression in NSCLC patients (n=50).
***P <0.001.
Figure 2. The potential application of
CD15+LOX-1+ PMN-MDSCs in NSCLC
diagnosis.
(A) Levels of CEA, CYFRA21-1, and CA125 in serum of NSCLC patients were
measured (n=50). (B) The correlation of
CD15+LOX-1+ PMN-MDSC frequency with
levels of tumor markers. (C) ROC curves. ***P <0.001.
Figure 3. Circulating CD15+LOX-1+PMN-MDSCs are associated with NSCLC prognosis and recurrence after
surgery.
(A) CD15+LOX-1+ PMN-MDSC frequency
in PB of NSCLC patients before (n=50) or after surgical resection
(n=50). (B) CD15+LOX-1+ PMN-MDSC
frequency in PB of NSCLC patients with (n=50) or without (n=50)
recurrence post-surgery. (C)
CD15+LOX-1+ PMN-MDSC frequency was
compared in traced NSCLC patients with (n=8) or without (n=3) recurrence
post-surgery. **P <0.01, ***P <0.001.